Trastuzumab-deruxtecan: Grade 3 neutropenia and interstitial lung disease.

A case study involving 11 women with recurrent breast cancer found that two of them developed grade 3 neutropenia or interstitial lung disease while being treated with trastuzumab-deruxtecan, a medication for HER2-positive breast cancer. One woman experienced neutropenia but her dose was reduced after she recovered. The other woman developed interstitial lung disease and was hospitalized, but later discharged after treatment with steroids. [Extracted from the article]